Zobrazeno 1 - 10
of 47
pro vyhledávání: '"Debu, Tripathy"'
Autor:
Brittany L. Murphy, Min Yi, Angelica M. Gutierrez Barrera, Debu Tripathy, Kelly K. Hunt, Banu K. Arun
Publikováno v:
Annals of Surgical Oncology. 30:1663-1668
Autor:
Brittany L, Murphy, Min, Yi, Angelica Gutierrez, Barrera, Debu, Tripathy, Kelly K, Hunt, Banu K, Arun
Publikováno v:
Annals of Surgical Oncology. 30:1669-1670
Autor:
Alexander Ring, Daniel Campo, Tania B. Porras, Pushpinder Kaur, Victoria A. Forte, Debu Tripathy, Janice Lu, Irene Kang, Michael F. Press, Young Ju Jeong, Anson Snow, Yue Zhu, Gabriel Zada, Naveed Wagle, Julie E. Lang
Publikováno v:
Annals of Surgical Oncology. 29:2897-2898
Autor:
Debu Tripathy, Carlos H. Barcenas, L. McCulloch, Manuel Ruiz-Borrego, Arlene Chan, Daniel Egle, Maureen E. Trudeau, Adam Brufsky, G. Marx
Publikováno v:
Breast, Vol 56, Iss, Pp S18-S19 (2021)
Autor:
S Moran, Ira Gore, D Kendall, Y Manalo, James L. Wade, Pearl Fang, A Kellum, Serena Wong, Andrew T. Chan, Carlos H. Barcenas, Debu Tripathy, V Hansen, Daniel Hunt, Nicholas Iannotti, Ricardo H. Alvarez, E Ibrahim, Elizabeth Olek, Mary Wilkinson, Sara A. Hurvitz, R Ruiz, Richard A. Bryce
Publikováno v:
Cancer Research. 77:P2-11
Background: Neratinib (Puma Biotechnology Inc) is an irreversible pan-HER inhibitor in late-phase development for the treatment of early-stage and metastatic HER2+ BC. Diarrhea, the main toxicity of neratinib, requires active management with loperami
Autor:
Terry David Church, Christy A. Russell, Debu Tripathy, Caroline I. Piatek, Richard Sposto, Stephen F. Sener, Chandan Kaur, Lingyun Ji, Agustin A. Garcia
Publikováno v:
Journal of Surgical Oncology. 114:917-921
Background and Objectives Routine staging imaging studies (RSIS) are optional in stage III breast cancer (BC). The impact of RSIS on treatment decisions and patient outcomes has not been extensively studied. The goal of this study was to determine wh
Autor:
Ronald S. Walters, Richard A. Ehlers, Carlos H. Barcenas, Henry Mark Kuerer, Thomas A. Buchholz, Seohyun Lee, Oluwadamilola M. Fayanju, Tracy E. Spinks, Tinisha L. Mayo, Rosa F. Hwang, Thomas W. Feeley, Kelly K. Hunt, Jesse C. Selber, Sharon H. Giordano, Benjamin Smith, Debu Tripathy
Publikováno v:
Annals of Surgical Oncology. 23:2385-2390
Value in healthcare-i.e., patient-centered outcomes achieved per healthcare dollar spent-can define quality and unify performance improvement goals with health outcomes of importance to patients across the entire cycle of care. We describe the proces
Autor:
Melody A. Cobleigh, Ginny Mason, Mary S. Beattie, Peter A. Kaufman, Adam Brufsky, Musa Mayer, Debu Tripathy, D. A. Yardley, Mohammad Jahanzeb, Bongin Yoo, S Hurvitz, Sandra M. Swain, HS Rugo, S Ogale, Joyce A. O'Shaughnessy
Publikováno v:
Cancer Research. 76:P6-17
Introduction HER2+ MBC patients with CNS metastases are often excluded from clinical trials. The Systemic Therapies for HER2+ Metastatic Breast Cancer Registry (SystHERs), a real-world, prospective registry study, is uniquely positioned to evaluate t
Autor:
Sharon H. Giordano, Vicente Valero, Rachel Ann Sanford, Mariana Chavez-MacGregor, Xiudong Lei, Elizabeth A. Mittendorf, Debu Tripathy, Abigail S. Caudle, Carlos H. Barcenas
Publikováno v:
Annals of Surgical Oncology. 23:1515-1521
No studies have examined the impact of the interval from conclusion of neoadjuvant chemotherapy to surgery in breast cancer patients. This study was undertaken to investigate the relationship between time interval from neoadjuvant chemotherapy to sur
Autor:
Neal Mineyev, Michael F. Press, Alexander Ring, Victoria Forte, Debu Tripathy, Pushpinder Kaur, Julie E. Lang, Daniel Campo, Tania B. Porras
Publikováno v:
Annals of surgical oncology. 25(8)
We characterized the whole transcriptome of circulating tumor cells (CTCs) in stage II–III breast cancer to evaluate correlations with primary tumor biology. CTCs were isolated from peripheral blood (PB) via immunomagnetic enrichment followed by fl